This includes decreased frequencies of IFN-γ-, IL-2-, and IL-17A-producing CD4 T cells, as well as IFN-γ- and IL-2-producing CD8 T cells.16 Tacrolimus is also widely used in lupus nephritis (LN), where it has shown non-inferiority to mycophenolate mofetil when combined with prednisolone in patients with biopsy-confirmed active LN.17,18 As Th17 cells and the cytokine IL-17A play a key role in LN pathogenesis,19 tacrolimus’s inhibitory effects on these pathways make it a compelling therapeutic option. Here, CD8A is linked to lobular neoplasia.